Unexpected toxicity after low-dose docetaxel treatment of a cancer patient with clinically latent HCV-positive hepatic cirrhosis

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2491-2492

  Koukourakis, Michael I ^a   Kapsoritakis, Andreas ^a   Maltezos, Efstratios ^a   Potamianos, Spiridon ^a   Mouzas, Ioannis ^a   Kouroumalis, Helias ^a  

^a Tumour/Angiogenesis Research Group   (Greece)

Author keywords

Docetaxel; HCV; Toxicity

Indexed keywords

DOCETAXEL;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DYSPHAGIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG ADENOCARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MOUTH INFECTION; MULTIMODALITY CANCER THERAPY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FATAL OUTCOME; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LYMPHOPENIA; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; TAXOIDS;

EID: 0036336732     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Relationships between the structure of taxol analogues and their antinitotic activity
2. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
3. Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle
4. Radiation sensitizing effects of Taxotere
5. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer
6. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial
7. Transection of the eosophagus for bleeding oesophageal varices
8. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
9. Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere®) in phase II studies
10. Pharmacodymanics of docetaxel (Taxotere®) in patients with liver metastases (METS)
11. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small cell lung carcinoma
12. Concurrent twice-a-week docetaxel and radiotherapy. A dose escalation trial with immunological toxicity evaluation
13. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemoradiotherapy: Additional chemotherapy enhances regression of residual cancer